Article
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Dec 2014
Zhou Q, Cheng Y, Yang J-J, Zhao M-F, Zhang L, Zhang X-C, Chen Z-H, Yan H-H, Song Y, Chen J-H, Feng W-N, Xu C-R, Wang Z, Chen H-J, Zhong W-Z, Liu Y-P, Wu Y-L
Abstract excerpt
BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.